Ek Sara, Andréasson Ulrika, Hober Sophia, Kampf Caroline, Pontén Fredrik, Uhlén Mathias, Merz Hartmut, Borrebaeck Carl A K
Department of Immunotechnology, Lund University, SE-22007 Lund, Sweden.
Mol Cell Proteomics. 2006 Jun;5(6):1072-81. doi: 10.1074/mcp.M600077-MCP200. Epub 2006 Mar 8.
Mantle cell lymphoma (MCL) is an aggressive lymphoid malignancy for which better treatment strategies are needed. To identify potential diagnostic and therapeutic targets, a signature consisting of MCL-associated genes was selected based on a comprehensive gene expression analysis of malignant and normal B cells. The corresponding protein epitope signature tags were identified and used to raise monospecific, polyclonal antibodies, which were subsequently analyzed on paraffin-embedded sections of malignant and normal tissue. In this study, we demonstrate that the initial selection strategy of MCL-associated genes successfully allows identification of protein antigens either uniquely expressed or overexpressed in MCL compared with normal lymphoid tissues. We propose that genome-based, affinity proteomics, using protein epitope signature tag-induced antibodies, is an efficient way to rapidly identify a number of disease-associated protein candidates of both previously known and unknown identities.
套细胞淋巴瘤（MCL）是一种侵袭性淋巴恶性肿瘤，需要更好的治疗策略。为了确定潜在的诊断和治疗靶点，基于对恶性和正常B细胞的全面基因表达分析，选择了一个由MCL相关基因组成的特征。鉴定了相应的蛋白质表位特征标签，并用于制备单特异性多克隆抗体，随后在恶性和正常组织的石蜡包埋切片上进行分析。在本研究中，我们证明，与正常淋巴组织相比，MCL相关基因的初始选择策略成功地允许鉴定在MCL中独特表达或过表达的蛋白质抗原。我们提出，基于基因组的亲和蛋白质组学，使用蛋白质表位特征标签诱导的抗体，是快速鉴定许多身份已知和未知的疾病相关蛋白质候选物的有效方法。
